Short-Term Changes in Intraocular Pressure After Intravitreal Injection of Bevacizumab for the Treatment of Retinopathy of Prematurity

Shumpei Obata,1 Tomoaki Higashiyama,1 Taku Imamura,1 Masashi Kakinoki,1 Takahide Yanagi,2 Yoshihiro Maruo,2 Masahito Ohji1 1Department of Ophthalmology, Shiga University of Medical Science, Otsu, Japan; 2Department of Pediatrics, Shiga University of Medical Science, Otsu, JapanCorrespondence: Shumpe...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Obata S, Higashiyama T, Imamura T, Kakinoki M, Yanagi T, Maruo Y, Ohji M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	retinopathy of prematurity intraocular pressure bevacizumab Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/d898a328897644628afeffa2d8aef362
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d898a328897644628afeffa2d8aef362
record_format	dspace
spelling	oai:doaj.org-article:d898a328897644628afeffa2d8aef3622021-12-02T07:39:55ZShort-Term Changes in Intraocular Pressure After Intravitreal Injection of Bevacizumab for the Treatment of Retinopathy of Prematurity1177-5483https://doaj.org/article/d898a328897644628afeffa2d8aef3622019-12-01T00:00:00Zhttps://www.dovepress.com/short-term-changes-in-intraocular-pressure-after-intravitreal-injectio-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Shumpei Obata,1 Tomoaki Higashiyama,1 Taku Imamura,1 Masashi Kakinoki,1 Takahide Yanagi,2 Yoshihiro Maruo,2 Masahito Ohji1 1Department of Ophthalmology, Shiga University of Medical Science, Otsu, Japan; 2Department of Pediatrics, Shiga University of Medical Science, Otsu, JapanCorrespondence: Shumpei ObataDepartment of Ophthalmology, Shiga University of Medical Science, Seta Tsukinowacho, Otsu, Shiga 520-2192, JapanTel +81-77-548-2276Fax +81-77-548-2279Email obata326@belle.shiga-med.ac.jpPurpose: To evaluate short-term changes in intraocular pressure after intravitreal injection of bevacizumab for retinopathy of prematurity.Patients and methods: This study was a prospective case-series. Consecutive infants underwent intravitreal injection with bevacizumab for type 1 retinopathy of prematurity at a university hospital. Intraocular pressure was measured with tonometer at baseline, at 1 min, and at 3, 10, 30 and 60 mins after injection.Results: Five patients (four boys) were enrolled in this study. Mean (± standard deviation) intraocular pressure was 8.0 ± 2.4 mmHg (range: 6–11.5 mmHg) just before the intravitreal injection, and the pressures were 19.8 ± 2.8 mmHg (16.4–23.9 mmHg), 14.6 ± 4.4 mmHg (7.6–18.4 mmHg), 11.2 ± 4.2 mmHg (6.4–16.5 mmHg), 9.3 ± 3.5 mmHg (5.8–13.2 mmHg), and 8.2 ± 1.4 mmHg (6.9–10.0 mmHg) at 1 min, 3, 10, 30 and 60 mins after the injection, respectively. Mean intraocular pressure after 1 min was significantly higher than intraocular pressure before injection (p = 0.02). Pressures decreased between 1 min and 3 mins after intravitreal injection, although there was no statistically significant difference between the pressures at those time-points. Intraocular pressures after 3, 10, 30 and 60 mins were not significantly different from the pressure before injection.Conclusion: Intraocular pressure elevation after intravitreal injection of bevacizumab for neonatal infants may be mild, so there may be a limited risk due to intraocular pressure after intraocular injection of bevacizumab for retinopathy of prematurity.Keywords: retinopathy of prematurity, intraocular pressure, bevacizumabObata SHigashiyama TImamura TKakinoki MYanagi TMaruo YOhji MDove Medical Pressarticleretinopathy of prematurityintraocular pressurebevacizumabOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 13, Pp 2445-2449 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	retinopathy of prematurity intraocular pressure bevacizumab Ophthalmology RE1-994
spellingShingle	retinopathy of prematurity intraocular pressure bevacizumab Ophthalmology RE1-994 Obata S Higashiyama T Imamura T Kakinoki M Yanagi T Maruo Y Ohji M Short-Term Changes in Intraocular Pressure After Intravitreal Injection of Bevacizumab for the Treatment of Retinopathy of Prematurity
description	Shumpei Obata,1 Tomoaki Higashiyama,1 Taku Imamura,1 Masashi Kakinoki,1 Takahide Yanagi,2 Yoshihiro Maruo,2 Masahito Ohji1 1Department of Ophthalmology, Shiga University of Medical Science, Otsu, Japan; 2Department of Pediatrics, Shiga University of Medical Science, Otsu, JapanCorrespondence: Shumpei ObataDepartment of Ophthalmology, Shiga University of Medical Science, Seta Tsukinowacho, Otsu, Shiga 520-2192, JapanTel +81-77-548-2276Fax +81-77-548-2279Email obata326@belle.shiga-med.ac.jpPurpose: To evaluate short-term changes in intraocular pressure after intravitreal injection of bevacizumab for retinopathy of prematurity.Patients and methods: This study was a prospective case-series. Consecutive infants underwent intravitreal injection with bevacizumab for type 1 retinopathy of prematurity at a university hospital. Intraocular pressure was measured with tonometer at baseline, at 1 min, and at 3, 10, 30 and 60 mins after injection.Results: Five patients (four boys) were enrolled in this study. Mean (± standard deviation) intraocular pressure was 8.0 ± 2.4 mmHg (range: 6–11.5 mmHg) just before the intravitreal injection, and the pressures were 19.8 ± 2.8 mmHg (16.4–23.9 mmHg), 14.6 ± 4.4 mmHg (7.6–18.4 mmHg), 11.2 ± 4.2 mmHg (6.4–16.5 mmHg), 9.3 ± 3.5 mmHg (5.8–13.2 mmHg), and 8.2 ± 1.4 mmHg (6.9–10.0 mmHg) at 1 min, 3, 10, 30 and 60 mins after the injection, respectively. Mean intraocular pressure after 1 min was significantly higher than intraocular pressure before injection (p = 0.02). Pressures decreased between 1 min and 3 mins after intravitreal injection, although there was no statistically significant difference between the pressures at those time-points. Intraocular pressures after 3, 10, 30 and 60 mins were not significantly different from the pressure before injection.Conclusion: Intraocular pressure elevation after intravitreal injection of bevacizumab for neonatal infants may be mild, so there may be a limited risk due to intraocular pressure after intraocular injection of bevacizumab for retinopathy of prematurity.Keywords: retinopathy of prematurity, intraocular pressure, bevacizumab
format	article
author	Obata S Higashiyama T Imamura T Kakinoki M Yanagi T Maruo Y Ohji M
author_facet	Obata S Higashiyama T Imamura T Kakinoki M Yanagi T Maruo Y Ohji M
author_sort	Obata S
title	Short-Term Changes in Intraocular Pressure After Intravitreal Injection of Bevacizumab for the Treatment of Retinopathy of Prematurity
title_short	Short-Term Changes in Intraocular Pressure After Intravitreal Injection of Bevacizumab for the Treatment of Retinopathy of Prematurity
title_full	Short-Term Changes in Intraocular Pressure After Intravitreal Injection of Bevacizumab for the Treatment of Retinopathy of Prematurity
title_fullStr	Short-Term Changes in Intraocular Pressure After Intravitreal Injection of Bevacizumab for the Treatment of Retinopathy of Prematurity
title_full_unstemmed	Short-Term Changes in Intraocular Pressure After Intravitreal Injection of Bevacizumab for the Treatment of Retinopathy of Prematurity
title_sort	short-term changes in intraocular pressure after intravitreal injection of bevacizumab for the treatment of retinopathy of prematurity
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/d898a328897644628afeffa2d8aef362
work_keys_str_mv	AT obatas shorttermchangesinintraocularpressureafterintravitrealinjectionofbevacizumabforthetreatmentofretinopathyofprematurity AT higashiyamat shorttermchangesinintraocularpressureafterintravitrealinjectionofbevacizumabforthetreatmentofretinopathyofprematurity AT imamurat shorttermchangesinintraocularpressureafterintravitrealinjectionofbevacizumabforthetreatmentofretinopathyofprematurity AT kakinokim shorttermchangesinintraocularpressureafterintravitrealinjectionofbevacizumabforthetreatmentofretinopathyofprematurity AT yanagit shorttermchangesinintraocularpressureafterintravitrealinjectionofbevacizumabforthetreatmentofretinopathyofprematurity AT maruoy shorttermchangesinintraocularpressureafterintravitrealinjectionofbevacizumabforthetreatmentofretinopathyofprematurity AT ohjim shorttermchangesinintraocularpressureafterintravitrealinjectionofbevacizumabforthetreatmentofretinopathyofprematurity
_version_	1718399309180829696

Short-Term Changes in Intraocular Pressure After Intravitreal Injection of Bevacizumab for the Treatment of Retinopathy of Prematurity

Ejemplares similares